BioMarin Pharmaceutical Inc. (BMRN)

95.58
2.02 2.07
NASDAQ : Health Technology
Prev Close 97.60
Open 95.20
Day Low/High 94.35 / 97.42
52 Wk Low/High 75.81 / 100.03
Volume 1.99M
Avg Volume 1.27M
Exchange NASDAQ
Shares Outstanding 176.71M
Market Cap 15.90B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Probing the Long Side of BioMarin

Probing the Long Side of BioMarin

Latest surge boosts chances of breakout in shares of BioMarin.

BioMarin Pharmaceutical Is Doing Better but Patience Is Needed

BioMarin Pharmaceutical Is Doing Better but Patience Is Needed

The upswing is welcomed but it still is not an important breakout of the two-year sideways pattern.

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.

What to Expect From Trump's Speech on Drug Prices on Friday

What to Expect From Trump's Speech on Drug Prices on Friday

Since taking office, President Trump has talked big on reining in drug prices, but the administration's lack of action leaves most expecting a May 11 speech that tastes like a nothing burger.

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Here's what you need to know for Monday, April 9.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

5 Top Stocks With 100% Buy Ratings Right Now

5 Top Stocks With 100% Buy Ratings Right Now

These five 'Strong Buy' stocks boast a double whammy of only buy ratings and big upside potential. After the market's recent plunge, this list is quite handy.

Why I Stay Very Focused on My Individual Stocks

Why I Stay Very Focused on My Individual Stocks

I do not need to come up with any grand arguments for a bullish or bearish bias. It happens by default.

7 Winners and Losers From Biggest Biotech Conference of 2017

7 Winners and Losers From Biggest Biotech Conference of 2017

Here are how some of the conference presenters are performing on the market Wednesday

Bluebird Bio Becoming Household Name With This Promising Cancer Treatment

Bluebird Bio Becoming Household Name With This Promising Cancer Treatment

Bluebird Bio stock is flying higher by 20% Monday, following an update of its promising cancer treatments, Jim Cramer said.

Allergan, BioMarin Hold Promise for 2018

Allergan, BioMarin Hold Promise for 2018

The stocks of these two larger-cap biopharma names seem poised to stage comebacks next year.

BioMarin Pharmaceutical Stock Sees Short Interest Expand By 10.3%

BioMarin Pharmaceutical Stock Sees Short Interest Expand By 10.3%

The most recent short interest data has been released for the 11/15/2017 settlement date, which shows a 842,388 share increase in total short interest for BioMarin Pharmaceutical Inc. , to 9,033,035, an increase of 10.28% since 10/31/2017.

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.

GOP Tax Fix Could Zero Out Orphan Drug Tax Credit

GOP Tax Fix Could Zero Out Orphan Drug Tax Credit

The hotly debated tax reform championed by the Trump White House needs to be paid for by spending cuts. One proposed change could eliminate the tax credit for companies developing treatments through the Orphan Drug Act.

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

There are a variety of players that should be active in the M&A space next year.

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Technology and biotech companies seem to be among the big winners.

BioMarin Pharmaceutical: Cramer's Top Takeaways

BioMarin Pharmaceutical: Cramer's Top Takeaways

JJ Bienaime, CEO of orphan drugmaker BioMarin Pharmaceutical, gives Jim Cramer an update on the company's drug portfolio.

Rally's Not Waiting on Tax Reform: Cramer's 'Mad Money' Recap (Wed 10/18/17)

Rally's Not Waiting on Tax Reform: Cramer's 'Mad Money' Recap (Wed 10/18/17)

Jim Cramer says Washington has, for years, had an inflated view of itself when it comes to passing legislation that helps the economy.

BioMarin Pharmaceutical Becomes #17 Most Shorted Nasdaq 100 Component, Replacing Mattel

BioMarin Pharmaceutical Becomes #17 Most Shorted Nasdaq 100 Component, Replacing Mattel

The most recent short interest data has been released for the 09/29/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Evercore ISI analyst Josh Schimmer is bullish on biotech.

Trump's FDA: A Friendlier Biotech Sheriff

Trump's FDA: A Friendlier Biotech Sheriff

There still will be winners and losers, but the new administration's FDA is a net plus for the industry.

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Big gains could be ahead for investors willing to stick with the stock, according to one firm.

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

My three top predictions for the next six months.

3 Fearless Predictions for the Second Half

3 Fearless Predictions for the Second Half

The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.

3 Fearless Predictions for the Second Half

3 Fearless Predictions for the Second Half

The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.

Cramer: These Sectors Look Bullish (Part III)

Cramer: These Sectors Look Bullish (Part III)

From Abbott Labs to Wynn, these names rate checking out.

TheStreet Quant Rating: D+ (Sell)